Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Next Previous
Drug Profile

Research programme: anti-inflammatory therapeutics - Omeros Corporation

Alternative Names: anti-MASP-2 monoclonal antibody - Omeros Corporation; MASP-2 therapeutics - Omeros Corporation; MASP-3 therapeutics - Omeros Corporation

Latest Information Update: 28 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Mannose-binding protein-associated serine protease inhibitors; MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute kidney injury; Age-related macular degeneration; Haemolytic uraemic syndrome; Inflammation; Myocardial reperfusion injury; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Stroke

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Intraperitoneal, Injection)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Parenteral)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top